ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
12/12/2024 ET
Phase 1b/2 presentation due at December 12, 2024. Phase 1b/2 first patient dosed, October 5, 2021.
Drug:
Zanidatamab and Evorpacept (ALX148)
HER2 Breast cancer and solid tumors
Strategy:
We may observe a slight pre-run-up leading into the presentation. If your position is in profit by that point, it’s wise to secure gains by taking at least partial profits, as the presentation’s outcome is highly speculative.
Key Insights on ALXO:
ALXO has a robust pipeline, presenting promising growth potential.
Key catalysts are expected by mid-2025, which could significantly impact the company’s valuation.
Overall Market Sentiment:
It’s always crucial to consider overall market sentiment when making trading decisions.
Breakout Zone:
$1.80
Resistance Point:
$1.95
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Risk/Money Management
Take Profit (TP): Set a target at $2.20
Stop Loss (SL): Set at under $1.50 to mitigate potential losses.
Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
- Float: 30.437M
- Short % of Float: 23.74%
12/12/2024 ET
Phase 1b/2 presentation due at December 12, 2024. Phase 1b/2 first patient dosed, October 5, 2021.
Drug:
Zanidatamab and Evorpacept (ALX148)
HER2 Breast cancer and solid tumors
Strategy:
We may observe a slight pre-run-up leading into the presentation. If your position is in profit by that point, it’s wise to secure gains by taking at least partial profits, as the presentation’s outcome is highly speculative.
Key Insights on ALXO:
ALXO has a robust pipeline, presenting promising growth potential.
Key catalysts are expected by mid-2025, which could significantly impact the company’s valuation.
Overall Market Sentiment:
It’s always crucial to consider overall market sentiment when making trading decisions.
Breakout Zone:
$1.80
Resistance Point:
$1.95
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Risk/Money Management
Take Profit (TP): Set a target at $2.20
Stop Loss (SL): Set at under $1.50 to mitigate potential losses.
Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
交易结束：到达止损
again SL hunt and bounce. fail
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。